RepliCel has completed phase 1 human clinical studies in hair loss due to androgenetic alopecia, aging & sun-damaged skin, and chronic Achilles tendinopathy.
Recently a randomized, double-blinded, placebo-controlled, dose-finding study was also completed in male and female patients with different stages of advanced hair loss dues to androgenic alopecia. With its partners, RepliCel is now moving as quickly as possible to next phase clinical studies of its programs in skin rejuvenation, tendon regeneration, and hair regrowth. These next-phase studies will be conducted in Japan and China.
If you are interested in signing up to stay informed or to register your interest in participating in a future trial (should one be located in your area), please visit the related product's study page.